Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced upcoming presentations at the 2026 ASCO and EULAR annual meetings, showcasing data from its off-the-shelf CAR T-cell therapy pipeline. The presentations will highlight clinical trial results for product candidates like FT836 for solid tumors and FT819 for autoimmune diseases, including Systemic Lupus Erythematosus (SLE), as well as a dual-CAR T-cell therapy, FT839, for autoimmune conditions. These presentations underscore the company's progress in developing iPSC-derived cellular immunotherapies for oncology and autoimmune disorders.
Fate Therapeutics (FATE) CEO executes 28,946-share sell-to-cover tax sale
Fate Therapeutics President and CEO Bahram Valamehr sold 28,946 shares of common stock at a weighted average price of $1.8822 per share. This automatic sale on May 20, 2026, was conducted to cover tax withholding obligations related to the vesting of 50,000 performance-based RSUs granted in July 2024. Following this transaction, Valamehr directly holds 635,762 shares and the sale was not discretionary, but rather an irrevocable sell-to-cover election.
Fate Therapeutics (FATE) officer sells 25,590 shares in tax-related transaction
Fate Therapeutics officer Cindy Tahl sold 25,590 shares of common stock at a weighted average price of $1.879 per share. This was a pre-arranged, non-discretionary "sell-to-cover" transaction to meet tax withholding obligations arising from the vesting of 50,000 performance-based RSUs. Following this sale, Tahl directly holds 628,155 shares of Fate Therapeutics common stock.
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced presentations at the 2026 ASCO and EULAR Annual Meetings, highlighting data from its off-the-shelf CAR T-cell programs. The presentations will feature preliminary Phase 1 results for FT836 targeting solid tumors at ASCO, and safety and efficacy data for FT819 in SLE, along with details on FT839 for autoimmune diseases, at EULAR. These presentations underscore the company's progress in developing iPSC-derived cellular immunotherapies for cancer and autoimmune conditions.
Fate Therapeutics to present CAR T-cell data at medical conferences
Fate Therapeutics (NASDAQ:FATE) is set to present new data from its CAR T-cell programs at two major medical conferences: the American Society of Cancer Oncology Annual Meeting and the European Congress of Rheumatology. The presentations will cover preliminary Phase 1 results for solid tumor and autoimmune disease therapies, including FT836, FT819, and FT839. Despite the company's innovative approach and recent stock momentum, InvestingPro notes its cash burn and unprofitability, though the stock is considered undervalued.
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced upcoming presentations at the 2026 ASCO and EULAR annual meetings, showcasing data from its off-the-shelf CAR T-cell programs for cancer and autoimmune diseases. Key presentations include preliminary Phase 1 results for FT836 in solid tumors at ASCO, and studies on FT819 for SLE and FT839 for autoimmune diseases at EULAR. The company emphasizes the potential of its iPSC-derived cellular immunotherapies to address limitations of traditional CAR T-cell therapies.
Off-the-shelf CAR T trials in cancer and autoimmune at 2026 ASCO, EULAR
Fate Therapeutics (NASDAQ:FATE) has announced its plans to present new data from its off-the-shelf, iPSC-derived CAR T-cell therapy pipeline at the 2026 ASCO and EULAR annual meetings. The presentations will cover product candidates FT836 for solid tumors and FT819/FT839 for lupus and other autoimmune diseases, highlighting Phase 1 safety and efficacy results. Following this news, the company's stock experienced a significant positive market reaction, gaining 12.77%.
Fate Therapeutics Announces Presentations at 2026 ASCO and EULAR Annual Meetings Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics announced presentations at the 2026 ASCO and EULAR annual meetings, showcasing data from its off-the-shelf CAR T-cell programs for cancer and autoimmune diseases. Key presentations include preliminary Phase 1 results for FT836 in solid tumors at ASCO, and safety and efficacy data for FT819 in SLE, along with information on FT839 for autoimmune diseases, at EULAR. The company emphasizes its iPSC-derived cellular immunotherapies designed to be readily available and broadly applicable.
[144] FATE THERAPEUTICS INC SEC Filing
This SEC filing for Fate Therapeutics Inc. (FATE) is a Form 144, indicating a proposed sale of securities. The filing, dated May 20, 2026, details the sale of 28,946 shares of common stock acquired through restricted stock vesting. The aggregate market value of the securities to be sold is $54,482.16.
Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Cell-based therapies are rapidly advancing, offering new approaches to anti-aging and neurodegenerative diseases by focusing on cellular repair and regeneration rather than just symptom management. The global cell therapy market is projected to grow significantly, driven by innovations in stem cells, regenerative biologics, and senolytic therapies. Companies like Avaí Bio, Geron Corporation, BioAge Labs, Lineage Cell Therapeutics, and Fate Therapeutics are making strides in developing treatments for age-related conditions, blood cancers, metabolic diseases, and neurodegenerative disorders.
Jefferies initiates Fate Therapeutics stock with buy rating on autoimmune potential
Jefferies has initiated coverage on Fate Therapeutics Inc. (NASDAQ:FATE) with a buy rating and a $4.00 price target, highlighting the potential of its lead program, FAT819, in autoimmune diseases. The company is advancing FAT819, an iPSC-derived CD19 CAR-T therapy, through Phase 1 trials for conditions like refractory systemic lupus erythematosus and lupus nephritis, with key updates expected later in 2026. This positive outlook is supported by recent promising Phase 1 data and the therapy's selection for an FDA development program, leading other analysts to raise their price targets.
Jefferies Initiates Fate Therapeutics(FATE.US) With Buy Rating, Announces Target Price $4
Jefferies has initiated coverage on Fate Therapeutics (FATE.US) with a Buy rating. The firm has set a target price of $4 for the company's stock.
Fate Therapeutics (FATE) Q1 Losses Reinforce Concerns Over Rich 35.1x P/S Valuation
Fate Therapeutics (FATE) reported Q1 revenue of US$1.3 million and a net loss of US$31.2 million, reinforcing concerns about its high 35.1x Price-to-Sales (P/S) valuation. Despite a forecast of 64.4% yearly revenue growth and a 9% annual reduction in losses over the past five years, the company remains heavily loss-making with trailing twelve-month losses of US$129.9 million, leaving little room for error if projected revenue growth doesn't materialize. Its current valuation significantly exceeds the US Biotech industry and peer averages.
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics reported its first-quarter 2026 financial results, highlighting significant progress in its clinical programs, particularly with FT819 for systemic lupus erythematosus (SLE) with lupus nephritis. The company is set to initiate a Phase 2 registrational trial for FT819 and has been accepted into the FDA's CDRP program, aiming for accelerated regulatory pathways. Financially, Fate Therapeutics extended its operating runway into 2028 through reduced operating expenses.
Fate Therapeutics (FATE) reports Q1 loss, misses revenue estimates
Fate Therapeutics (FATE) reported a wider loss and missed revenue estimates for the first quarter. The company posted a loss of $0.66 per share, compared to an expected loss of $0.58 per share by analysts, and revenue of $4.5 million, falling short of the $5.9 million consensus forecast. This indicates a challenging quarter for the biotechnology firm.
Fate Therapeutics Releases Q1 2026 Financial Results
Fate Therapeutics Inc. reported a Q1 2026 net loss of $31.2 million, or $0.26 per share, which was an improvement from the $0.32 per share loss in Q1 2025. Revenue for the quarter was $1.3 million, down from $1.6 million in the prior year, as the biopharmaceutical company continues to advance its clinical-stage pipeline. Wall Street analysts maintain a cautiously optimistic stance with mixed buy and hold ratings for the stock.
Fate Therapeutics (FATE) Reports Q1 Loss, Misses Revenue Estimates
Fate Therapeutics (FATE) reported a Q1 loss of $0.26 per share, outperforming the Zacks Consensus Estimate of a $0.29 loss, marking this an earnings surprise of over 10%. However, the company missed revenue estimates, posting $1.3 million against an expectation of $1.75 million. The stock has seen a significant 129% gain year-to-date, outperforming the S&P 500's 8.1% gain.
Fate Therapeutics 1Q 2026: Revenue $1.3M, EPS $(0.26) — 10-Q Summary
Fate Therapeutics reported its first-quarter 2026 results, with revenue reaching $1.3M and a net loss narrowing to $31.2M compared to the previous year. The company's diluted EPS improved to $(0.26), reflecting continued collaboration revenue from Ono and moderated R&D spending. Fate Therapeutics expects its current cash and investments of $174.8M to fund operations for at least 12 months.
Fate Therapeutics (NASDAQ: FATE) trims Q1 loss, extends cash runway and advances FT819
Fate Therapeutics reported a narrower net loss in Q1 2026, with operating expenses down 20% year-over-year, and extended its cash runway into 2028. The company advanced its lead iPSC-derived cell therapy, FT819, by gaining FDA selection into the CMC Development and Readiness Pilot program and planning a Phase 2 registrational study for lupus nephritis. Additionally, next-generation programs FT839 and FT836 showed progress in preclinical and early-stage clinical trials, respectively.
Fate Therapeutics: Q1 Earnings Snapshot
Fate Therapeutics Inc. (FATE) reported a first-quarter loss of $31.2 million, or 26 cents per share, outperforming Wall Street's expectation of a 29-cent loss per share. The clinical-stage biotech company generated $1.3 million in revenue during the period. The results were generated by Automated Insights using data from Zacks Investment Research.
Fate Therapeutics Reports First Quarter 2026 Financial Results and Business Updates
Fate Therapeutics announced its first-quarter 2026 financial results, highlighting plans to initiate the Phase 2 RECLAIM-LN clinical trial for FT819 in lupus nephritis in the second half of 2026. The company also reported FT819's selection for the FDA's CDRP program and positive preclinical data for FT839 and FT836. Fate Therapeutics extended its operating runway into 2028 due to reduced operating expenses.
Fate Therapeutics earnings beat by $0.02, revenue topped estimates
Fate Therapeutics (NASDAQ: FATE) reported first-quarter earnings per share of $-0.26, surpassing analyst estimates by $0.02, and revenue of $1.3 million, which also topped consensus estimates. The company's stock has seen significant growth, up 80% in the last three months and over 103% in the last year, with a "fair performance" financial health rating from InvestingPro.
Fate Therapeutics: Q1 Earnings Snapshot
Fate Therapeutics Inc. (FATE) reported a first-quarter loss of $31.2 million, or 26 cents per share, which exceeded Wall Street expectations. Analysts surveyed by Zacks Investment Research had estimated a loss of 29 cents per share. The clinical-stage biotech company also posted revenue of $1.3 million for the quarter.
FATE SEC Filings - Fate Therapeutic 10-K, 10-Q, 8-K Forms
This article provides an overview of Fate Therapeutics (FATE) SEC filings available on StockTitan, detailing the types of reports filed, such as 10-K, 10-Q, and 8-K, which document its biopharmaceutical business and cellular immunotherapy pipeline. It highlights that StockTitan tracks 34 filings for FATE, including summaries, impact scoring, and sentiment analysis. The most recent filing date mentioned is August 4, 2025.
Fate Therapeutics presents CAR T-cell therapy data at ASGCT
Fate Therapeutics (NASDAQ:FATE) showcased promising data from its CAR T-cell therapy programs at the ASGCT Annual Meeting, including positive Phase 1 results for FT819 in systemic lupus erythematosus and encouraging preclinical data for FT839 and FT836. These updates coincide with the company's stock trading near its 52-week high, and the FT819 therapy has been selected for the FDA's CMC Development and Readiness Pilot Program. Analysts have reacted positively, with H.C. Wainwright raising its price target to $7 and Mizuho reiterating an Outperform rating with an $8 price target.
Fate Therapeutics Showcases FT819 Clinical Activity in SLE
Fate Therapeutics presented data at the ASGCT Annual Meeting showcasing the clinical activity of its off-the-shelf CAR T-cell programs FT819, FT839, and FT836. FT819 demonstrated positive clinical responses in SLE patients without conditioning chemotherapy, achieving B cell remodeling and lupus low disease activity. Preclinical data for FT839 and FT836 highlighted their potential for targeting multicellular diseases and various cancers, respectively, also with reduced or no need for intensive conditioning chemotherapy.
Fate Therapeutics Showcases FT819 Clinical Activity in SLE
Fate Therapeutics showcased positive clinical data for its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the 2026 ASGCT Annual Meeting. FT819 demonstrated efficacy in systemic lupus erythematosus (SLE) patients without conditioning chemotherapy, achieving lupus low disease activity and B cell remodeling. Preclinical data for FT839 and FT836 also showed promising results for autoimmune diseases and cancer, respectively, highlighting the potential for less intensive or no conditioning chemotherapy in cellular immunotherapies.
Single-dose lupus therapy shows responses without conditioning chemo
Fate Therapeutics (NASDAQ: FATE) presented new data at the 2026 ASGCT Annual Meeting, showcasing clinical activity of its off-the-shelf CAR T-cell therapy FT819 in Systemic Lupus Erythematosus (SLE) patients without requiring conditioning chemotherapy. The study demonstrated meaningful clinical responses, including B-cell depletion lasting up to 12 months, and highlighted progress in its FT839 and FT836 programs for autoimmune diseases and cancer, respectively. The company emphasizes the potential for broader patient accessibility by eliminating intensive conditioning chemotherapy.
Fate Therapeutics Showcases FT819 Clinical Activity in SLE
Fate Therapeutics presented data on its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the ASGCT Annual Meeting. FT819 demonstrated clinical activity in Systemic Lupus Erythematosus (SLE) patients without conditioning chemotherapy, showing B cell remodeling and favorable safety. Preclinical data for FT839 and FT836 highlighted their potential for targeting multicellular diseases and various cancers, respectively, also emphasizing treatment without intensive chemotherapy.
Number of shareholders of Fate Therapeutics, Inc. – NASDAQ:FATE
This article focuses on the number of shareholders for Fate Therapeutics, Inc. (NASDAQ: FATE). It states that the information regarding the number of shareholders is available for a specific period, along with its value and percentage change. The content highlights the financial data provided by ICE Data Services and FactSet for the company.
Fate Therapeutics Inc (FATE) News, Articles, Events & Latest Updates
This page provides recent news and financial data for Fate Therapeutics Inc (FATE). Key updates include its upcoming Q1 2026 earnings report, analyst recommendations averaging "Hold," progress in CAR T-cell therapies for lupus and solid tumors, and a recent drop in short interest. The stock's current trading data and market capitalization are also presented.
Fate Therapeutics (FATE) officer exercises 166,664 options, holds 609k shares
Fate Therapeutics officer Cindy Tahl exercised stock options to acquire 166,664 shares of FATE common stock on May 6, 2026. This transaction involved exercising options at $1.05 and $1.32 per share, and she now directly holds 609,301 shares. The exercises were compensation-related and no open-market sales were reported.
Fate Therapeutics Inc (FATE) Stock Price Today & Analysis
This article provides an analysis of Fate Therapeutics Inc (FATE) stock, including its current price, fundamental financials, and company overview. It also offers essential FAQs for potential investors on how to buy FATE stock via the Gotrade app, minimum investment, dividend information, and safety regulations. The company is a clinical-stage biopharmaceutical firm focused on developing cellular immunotherapies for cancer and autoimmune disorders.
Director at Fate Therapeutics (NASDAQ: FATE) exercises 25,000 stock options
Robert S. Epstein, a director at Fate Therapeutics (NASDAQ: FATE), exercised stock options to acquire 25,000 shares of common stock at $1.69 per share. This transaction increased his direct holdings to 36,331 shares. The options had vested on the date of the company's 2017 Annual Meeting of Stockholders and were fully exercised, leaving no derivative securities remaining.
FATE Therapeutics (NASDAQ: FATE) director exercises options, boosts direct stake
William H. Rastetter, a director at FATE Therapeutics (NASDAQ: FATE), has exercised stock options to acquire 25,000 shares of common stock at $1.69 per share. This transaction increases his direct holdings to 36,331 shares. Additionally, Rastetter indirectly holds 459,272 shares through The Investment 2002 Trust and 146,821 shares via The Rastetter Family Trust, where he serves as a trustee.
Piper Sandler Maintains Fate Therapeutics(FATE.US) With Buy Rating, Maintains Target Price $6
Piper Sandler has reiterated its Buy rating for Fate Therapeutics (FATE.US) and maintained its price target of $6. The firm's assessment indicates continued confidence in the company's prospects.
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics announced that its investigational therapy FT819 has been selected for the U.S. FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot (CDRP) Program. This program, combined with FT819's existing Regenerative Medicine Advanced Therapy (RMAT) designation, aims to accelerate the manufacturing readiness and regulatory pathway for the drug. FT819 is an off-the-shelf CAR T-cell therapy candidate for moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, designed for broad patient accessibility and outpatient administration.
FDA selects Fate Therapeutics’ FT819 for manufacturing pilot program
The FDA has chosen Fate Therapeutics' FT819 therapy for its Chemistry, Manufacturing and Controls Development and Readiness Pilot Program. This program is for investigational therapies treating serious diseases with unmet medical needs, and FT819, an off-the-shelf CAR T-cell therapy for autoimmune disorders like systemic lupus erythematosus, previously received RMAT designation. The selection will lead to increased communication with the FDA, including additional CMC-focused meetings, to clarify development strategies and support manufacturing readiness.
Fate Therapeutics (FATE) Expected to Announce Quarterly Earnings on Tuesday
Fate Therapeutics (NASDAQ:FATE) is scheduled to release its Q1 2026 earnings before market open on Tuesday, May 12th. Analysts project earnings of ($0.29) per share and revenue of $1.491 million for the quarter. The company will hold an earnings call on Thursday, May 14th at 9:30 AM ET.
Fate Therapeutics Announces Three Presentations at the 2026
Fate Therapeutics will present data from three of its off-the-shelf CAR T-cell programs—FT819, FT839, and FT836—at the 2026 ASGCT Annual Meeting. The presentations will highlight clinical and translational data for FT819 in lupus, an oral presentation on FT839 for autoimmune diseases, and preclinical data for FT836 targeting pan-tumor stress ligands. The company aims to showcase its innovative iPSC-derived cellular immunotherapies for cancer and autoimmune conditions.
Fate Therapeutics Selected For U.S. FDA Chemistry, Manufacturing, And Controls Development And Readiness Pilot Program To Support Manufacturing Readiness Of Ft819
Fate Therapeutics has been chosen for the U.S. FDA's Chemistry, Manufacturing, and Controls (CMC) Development and Readiness Pilot Program. This selection aims to support the manufacturing readiness of their product, FT819. The program is designed to help companies prepare their manufacturing processes for FDA approval.
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics' FT819, an off-the-shelf anti-CD19 CAR T-cell therapy, has been selected for the U.S. FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program. This selection, combined with its existing Regenerative Medicine Advanced Therapy (RMAT) designation, aims to accelerate manufacturing readiness and expedite the regulatory pathway for its Phase 2 clinical trial in systemic lupus erythematosus (SLE). The program will facilitate enhanced communication and regulatory guidance to ensure timely market readiness for FT819.
FDA picks Fate's lupus cell therapy for manufacturing-readiness pilot
Fate Therapeutics' FT819, an off-the-shelf iPSC-derived anti-CD19 CAR T candidate for lupus, has been selected for the FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) program. This selection, combined with its existing RMAT designation, aims to accelerate manufacturing readiness and regulatory engagement for a planned Phase 2 potentially registrational trial in systemic lupus erythematosus (SLE) with lupus nephritis. The program is designed to prevent manufacturing bottlenecks from delaying product approvals for therapies with expedited clinical development timelines.
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics (NASDAQ: FATE) announced three presentations at the 2026 ASGCT Annual Meeting. These presentations will highlight data from their off-the-shelf CAR T-cell programs: FT819 for systemic lupus erythematosus, FT839 for autoimmune diseases, and FT836 for cancer. The data showcases their innovative approaches to cellular immunotherapies for difficult-to-treat conditions.
Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819
Fate Therapeutics announced that its FT819 therapy has been selected for the U.S. FDA's Chemistry, Manufacturing, and Controls Development and Readiness Pilot (CDRP) Program. This selection, combined with its existing Regenerative Medicine Advanced Therapy (RMAT) designation, aims to accelerate the manufacturing readiness and regulatory pathway for FT819, particularly in its Phase 2 clinical trial for moderate-to-severe systemic lupus erythematosus. The program is expected to facilitate enhanced FDA engagement and communication for the off-the-shelf CAR T-cell therapy, making it more accessible to patients.
Off-the-shelf CAR-T studies target lupus, diabetes and cancer
Fate Therapeutics (NASDAQ: FATE) announced it will present clinical and preclinical data for its CAR T-cell pipeline, including FT819, FT839, and FT836, at the 2026 ASGCT Annual Meeting. The presentations will highlight off-the-shelf approaches for both cancer and autoimmune diseases such as lupus and type 1 diabetes, featuring therapies designed to work without conditioning chemotherapy. The company's unique iPSC-derived cellular immunotherapies target multiple antigens for enhanced efficacy.
Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseases
Fate Therapeutics (NASDAQ: FATE) announced that it will present data from its off-the-shelf CAR T-cell programs FT819, FT839, and FT836 at the 2026 ASGCT Annual Meeting. The presentations will cover clinical and translational data for FT819 in systemic lupus erythematosus, an oral presentation on FT839 for autoimmune diseases, and preclinical data for FT836 for various cancers. These presentations highlight the company's progress in developing iPSC-derived cellular immunotherapies for difficult-to-treat conditions.
H.C. Wainwright raises Fate Therapeutics price target to $7 on SLE data
H.C. Wainwright increased its price target for Fate Therapeutics (NASDAQ:FATE) to $7 from $5, maintaining a Buy rating, following positive clinical data for its FT819 therapy in systemic lupus erythematosus (SLE) patients. The company's stock has shown significant gains, and it is considered undervalued by InvestingPro analysis, with further clinical updates expected later in 2026. Other analysts like Mizuho and Baird have also provided updates, with Mizuho maintaining an Outperform rating and Baird a Neutral rating, focusing on the potential for registrational trials and financial performance.
FATE Stock Rises As Fate Therapeutics Showcases FT839 CAR T Data
Fate Therapeutics Inc. (FATE) saw its stock rise by 19.2% due to promising preclinical data for its next-generation CAR T-cell candidate, FT839, which will be presented at AACR 2026. Despite weak fundamentals and negative margins, the company maintains adequate near-term liquidity with $204M in cash, providing a multi-year runway. Analysts view FATE as a speculative buy, given the high-risk, high-optionality nature of its allogeneic platform, with near-term catalysts expected from the FT839 data.
Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)
Fate Therapeutics Inc. announced a new inducement award, granting restricted stock units representing 30,200 shares of common stock to a newly hired non-executive employee. This grant, approved by the Compensation Committee, is made under the Company’s Amended and Restated Inducement Equity Plan in accordance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting annually, contingent on continuous employment.
